An update on Dexcom's 2026 plans with changes in senior leadership and a push for wider access to CGM technology.
We reflect on Dexcom's performance in 2025 and get up-to-date with news of their plans for a G8 sensor and international expansion.
News that approval from the FDA of the Dexcom G7 15 day CGM in the US, with a grace period of 12 hours, makes this the longest lasting CGM.
Dexcom's financial filings reveal a warning letter from the FDA regarding processing in 2 of its manufacturing plants.
News that Abbott and Dexcom have agreed not to sue each other for patents relating to their CGM tech for another 10 years.
